

## Editorial

# A Bim-activating mould

G Häcker<sup>\*,1</sup>

*Cell Death and Differentiation* (2013) 20, 1289–1290; doi:10.1038/cdd.2013.98

*Aspergillus fumigatus* is a mould found basically everywhere: in water, soil, food, in decaying matter (for instance in your rubbish bin) and floating through the air.<sup>1</sup> The genus *Aspergillus* (and here by far the most common one is *A. fumigatus*) can also cause invasive aspergillosis, a difficult-to-diagnose and life-threatening condition in immunosuppressed patients<sup>2</sup> (Figure 1). *A. fumigatus* has a well-stocked arsenal of factors that are thought to contribute to its virulence.<sup>3</sup> In this issue of the journal, Geissler *et al.*<sup>4</sup> show that one of the prominent toxins of *A. fumigatus*, gliotoxin, induces apoptosis in a number of mammalian cells through a signalling pathway involving the JNK-dependent phosphorylation of the BH3-only protein Bim. This finding provides new insight into the activation of Bim and also adds to our understanding of the details of our co-existence with a ubiquitous fungus.

Bim is perhaps the most prominent of the BH3-only proteins. Judging by the phenotype of the various gene-deficient mouse strains generated, Bim is the most important BH3-only protein in the immune system, where it participates in apoptosis induction in most cell types and most situations tested.<sup>5,6</sup> BH3-only proteins are considered the sensors of the mitochondrial apoptosis pathway:<sup>7</sup> they are the most upstream components in the Bcl-2 family, which regulates mitochondrial apoptosis.

The Bcl-2-protein family has three subgroups. The effectors, Bax and Bak, release cytochrome-*c* from the mitochondria. The BH3-only proteins can, when experimentally overexpressed, with varying potency activate Bax and Bak; in a world of numerous molecular uncertainties like mitochondrial apoptosis, the knowledge is reassuringly stable that BH3-only proteins require Bax or Bak to induce apoptosis. The third group of Bcl-2 family proteins, the anti-apoptotic proteins (including Bcl-2 itself), block apoptosis by binding to the pro-apoptotic ones. They can bind the members of both groups, but the neutralisation of BH3-only proteins seems to be more important than the binding of Bax and Bak.<sup>8</sup>

Besides this sensing of apoptotic stimuli by BH3-only proteins, stimuli may also be sensed by anti-apoptotic proteins. This has been most extensively studied for Mcl-1, which is lost in response to many signals, and this loss may free BH3-only proteins for the activation of Bax/Bak.<sup>9</sup> On this framework, we have to identify the molecular mechanisms of how the chain of events in the Bcl-2 family is set off, starting from the generation of active BH3-only proteins, and here

Geissler *et al.*<sup>4</sup> provide new information. Their data argue for a role of Bim in the sensing of signals delivered by the c-jun NH<sub>2</sub>-terminal kinases 1 and 2 (JNK1/2).


JNKs are MAP kinases. They are activated by cytokines and by stress stimuli and can initiate a number of biological responses of the cell such as differentiation, inflammatory responses, proliferation and, relevant here, apoptosis.<sup>10</sup> Many reports demonstrate that JNKs can activate mitochondrial apoptosis (reviewed in Weston and Davis<sup>10</sup>). However, the proposed mechanisms differ substantially and range from inactivation by phosphorylation of anti-apoptotic proteins over the transcriptional induction of Bim to its direct phosphorylation. A JNK-phosphorylation site (T112) has been identified previously in Bim, but a knock-in mouse where this site had been mutated had only very modest changes in apoptosis.<sup>11</sup>

Geissler *et al.*<sup>4</sup> now show that gliotoxin-induced apoptosis to a substantial degree depends on the presence of Bim. They also confirm their earlier results<sup>12</sup> that gliotoxin requires Bak for full activity, whereas the contribution of Bax is only minor. Importantly, this recent work identifies two additional JNK-phosphorylation sites in Bim and demonstrates that all three sites have to be mutated to prevent gliotoxin-induced apoptosis. The approach taken may have technical issues because for this analysis mutant Bim forms were re-introduced into Bim-deficient cells under a retroviral promoter, which may subject the cells to a selection bias. However, taking the data at face value, they show impressively that triple-mutated Bim is inactive at transmitting the gliotoxin-JNK-initiated apoptotic stimulus to Bak.

What is happening at the molecular level? The data indicate that gliotoxin induces JNK activation from the plasma membrane (at variance with an earlier suggestion that it directly activates Bak at mitochondria<sup>12</sup>) and that this activation is necessary (although it may not be sufficient) to initiate Bak activation. It is suggested that the phosphorylated Bim is released from the cytoskeleton more efficiently. Such release was suggested 14 years ago<sup>13</sup> but has not received much experimental support since, and more recent data dispute at least the generality of this mechanism.<sup>14</sup> Geissler *et al.*<sup>4</sup> also show that gliotoxin treatment fails to increase Bcl-2 or Bcl-X<sub>L</sub> precipitation with Bim-phosphorylation site mutants, whereas it does for wt Bim. One way of interpreting this piece of data is that mutant Bim is less active as it cannot inhibit these anti-apoptotic proteins as strongly.

<sup>1</sup>Department of Medical Microbiology and Hygiene, University Medical Center Freiburg, Freiburg, Germany

\*Corresponding author: G Häcker, Department of Medical Microbiology and Hygiene, University Medical Center Freiburg, Hermann-Herder-Str. 11, D-79104 Freiburg, Germany. Tel: +49 761 203 6531; Fax: +49 761 203 6551; E-mail: georg.haecker@uniklinik-freiburg.de



**Figure 1** (a) Microscopy from a culture of *A. fumigatus* (lactophenol blue stain). The name *Aspergillus* was introduced in 1729 because of the similarity to the aspergillum, the implement used to sprinkle the holy water. (b) Invasive aspergillosis. *Aspergillus* hyphae invade in this case the gut epithelium (arrows). Credits: Annerose Serr (A) and Annette Schmitt-Gräff (B), University Medical Center Freiburg

However, it is very much under dispute whether Bim-Bcl-2-binding means that Bim inhibits Bcl-2 or that Bcl-2 inhibits Bim.<sup>15</sup> The binding studies by Geissler *et al.*<sup>4</sup> may therefore reflect any 'activation' of Bim and the associated binding of Bim to Bcl-2, and the observed differences may reflect reduced upstream signals. Whether this is linked to release of Bim from the cytoskeleton, from anti-apoptotic proteins (which may be downregulated as a response to gliotoxin) or any other molecular event is not clear at this stage. That the molecular details of JNK-Bim-dependent, gliotoxin-triggered apoptosis are uncertain is also highlighted by its reliance on Bak. Bim can efficiently also activate Bax.<sup>7</sup> That it does not in this study indicates that other mechanisms are relevant that have not yet been discovered. However, the data provide one of the few examples where upstream signalling is with only few gaps linked to the Bcl-2 family.

Gliotoxin from *Aspergillus* thus induces Bim/Bak-dependent apoptosis. Although the evidence that gliotoxin is an important virulence factor is equivocal,<sup>16</sup> such apoptosis induction may well be relevant to human invasive aspergillosis. It is unlikely that apoptosis induction, or any other effect on human cells, is the benefit that *Aspergillus* derives from gliotoxin production. It is certainly correct that *A. fumigatus* is the most common mould in invasive human disease, that the incidence of invasive aspergillosis has risen substantially in recent years and that these cases have a poor prognosis. However, given the ubiquitous existence of *Aspergillus* in nature and the rarity of aspergillosis in immunocompetent hosts, it seems very unlikely that the capacity for human infection is a relevant factor driving *Aspergillus* evolution. Gliotoxin may therefore have functions outside the human host.

A major risk factor predisposing humans to aspergillosis is the lack of functional neutrophils, and in neutropenic mice the lack of gliotoxin did not alter *Aspergillus* virulence (although it did in non-neutropenic mice).<sup>3,16</sup> This does not exclude a relevant role of gliotoxin in human invasive infections. Gliotoxin-dependent apoptosis induction may well affect severity and course of *Aspergillus* infection, for instance by destroying lung epithelium or by killing alveolar macrophages. Just as *Aspergillus* does not rely on humans for its niche in nature but can nevertheless cause severe infections, gliotoxin may have another function but may, given the chance, have effects on the human host. In any case, the report by Geissler *et al.*<sup>4</sup> uncovers new ways in the multi-faceted interaction of human cells with their environment and may have hit upon a new way of stress response that is relevant to a broader array of situations.

1. Summerbell R, Howard DH (eds). *Pathogenic Fungi in Humans and Animals*. 2nd edn. Marcel Dekker: New York, 2003. pp 237–498.
2. Walsh TJ *et al.* *Clin Infect Dis* 2008; **46**: 327–360.
3. Abad A *et al.* *Revista iberoamericana de micología* 2010; **27**: 155–182.
4. Geissler A *et al.* *Cell Death Differ* 2013; **20**: 1317–1329.
5. Strasser A. *Nat Rev Immunol* 2005; **5**: 189–200.
6. Happo L, Strasser A, Cory S. *J Cell Sci* 2012; **125**: 1081–1087.
7. Chipuk JE *et al.* *Mol Cell* 2010; **37**: 299–310.
8. Llambi F *et al.* *Mol Cell* 2011; **44**: 517–531.
9. Stewart DP *et al.* *Mol Cell Biol* 2010; **30**: 3099–3110.
10. Weston CR, Davis RJ. *Curr Opin Cell Biol* 2007; **19**: 142–149.
11. Hubner A *et al.* *Mol Cell* 2008; **30**: 415–425.
12. Pardo J *et al.* *J Cell Biol* 2006; **174**: 509–519.
13. Puthalakath H *et al.* *MolCell* 1999; **3**: 287–296.
14. Wilfling F *et al.* *Cell Death Differ* 2012; **19**: 1328–1336.
15. Villunger A *et al.* *Cell Death Differ* 2011; **18**: 1545–1546.
16. Scharf DH *et al.* *Appl Microbiol Biotechnol* 2012; **93**: 467–472.